Advances in the treatment of JAK2 V617F gene mutation positive myeloproliferative neoplasms
10.3760/cma.j.issn.1009-9921.2015.07.003
- VernacularTitle:JAK2 V617F基因突变阳性骨髓增殖性肿瘤治疗研究进展
- Author:
Fengru LIN
;
Yan WANG
;
Jingyu ZHANG
- Publication Type:Journal Article
- Keywords:
Myeloproliferative neoplasms;
JAK2 V617F gene mutation;
Therapy
- From:
Journal of Leukemia & Lymphoma
2015;24(7):392-393
- CountryChina
- Language:Chinese
-
Abstract:
JAK2 V617F gene mutation positive myeloproliferative neoplasms (MPN) consists of polycythemia vera (PV),essential thrombocythemia (ET) and primary myelofibrosis (PMF).This article focuses on their risk scoring systems and treatment including first-and second-line therapies,JAK2 inhibitors,cytoreduction,antifibrosis and other single-agent or combination therapy.
